Personalized Critical Care Medicine: How Far Away Are We?

Seminars in Respiratory and Critical Care Medicine

Volumn 36, Issue 6, 2015, Pages 809-822

  Ahasic, Amy M ^a   Christiani, David C ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

ARDS; biomarkers; critical care; genetics; personalized medicine; pharmacogenomics; sepsis

Indexed keywords

BIOLOGICAL MARKER;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; CRITICAL ILLNESS; DISEASE CLASSIFICATION; DISEASE SEVERITY; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC MARKER; HUMAN; HUMAN GENOME PROJECT; INTENSIVE CARE; INTENSIVE CARE UNIT; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT CARE; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; SEPSIS; TREATMENT RESPONSE; GENOMICS; ORGANIZATION AND MANAGEMENT; PROCEDURES; RESPIRATORY DISTRESS SYNDROME, ADULT; RISK FACTOR; TRENDS;

BIOMARKERS; CRITICAL CARE; CRITICAL ILLNESS; GENOMICS; HUMANS; INTENSIVE CARE UNITS; PRECISION MEDICINE; RESPIRATORY DISTRESS SYNDROME, ADULT; RISK FACTORS; SEPSIS;

EID: 84947939730     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0035-1564852     Document Type: Article

References (140)

1. Collins F. S. Shattuck lecture--medical and societal consequences of the Human Genome Project. N Engl J Med: 1999; 341 1 28 37
2. Hood L. Systems biology: integrating technology, biology, and computation. Mech Ageing Dev: 2003; 124 1 9 16
3. Hood L., Friend S. H. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol: 2011; 8 3 184 187
4. Agustí A., Antó J. M., Auffray C., et al. Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014. Am J Respir Crit Care Med: 2015; 191 4 391 401
5. Wendon J. Critical care normality: individualized versus protocolized care. Crit Care Med: 2010; 38 (10, Suppl): S590 S599
6. Barochia A. V., Cui X., Eichacker P. Q. The Surviving Sepsis Campaign's revised sepsis bundles. Curr Infect Dis Rep: 2013; 15 5 385 393
7. Shah R. R., Shah D. R. Personalized medicine: is it a pharmacogenetic mirage? Br J Clin Pharmacol: 2012; 74 4 698 721
8. Hamburg M. A., Collins F. S. The path to personalized medicine. N Engl J Med: 2010; 363 4 301 304
9. Allen J. M., Gelot S. Pharmacogenomics in the intensive care unit: focus on potential implications for clinical practice. Recent Pat Biotechnol: 2014; 8 2 116 122
10. Freeman B. D., McLeod H. L. Challenges of implementing pharmacogenetics in the critical care environment. Nat Rev Drug Discov: 2004; 3 1 88 93
11. Bodin L., Verstuyft C., Tregouet D. A., et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood: 2005; 106 1 135 140
12. McGuire M. C., Nogueira C. P., Bartels C. F., et al. Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc Natl Acad Sci U S A: 1989; 86 3 953 957
13. Hamdy S. I., Hiratsuka M., Narahara K., et al. Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Br J Clin Pharmacol: 2003; 55 6 560 569
14. Zineh I., Pacanowski M., Woodcock J. Pharmacogenetics and coumarin dosing--recalibrating expectations. N Engl J Med: 2013; 369 24 2273 2275
15. Kimmel S. E., French B., Kasner S. E., et al. COAG Investigators. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med: 2013; 369 24 2283 2293
16. Pirmohamed M., Burnside G., Eriksson N., et al. EU-PACT Group. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med: 2013; 369 24 2294 2303
17. Holliday S. F., Kane-Gill S. L., Empey P. E., Buckley M. S., Smithburger P. L. Interpatient variability in dexmedetomidine response: a survey of the literature. ScientificWorldJournal: 2014; 2014 14 805013
18. Choi L., Caffo B. S., Kohli U., et al. A Bayesian hierarchical nonlinear mixture model in the presence of artifactual outliers in a population pharmacokinetic study. J Pharmacokinet Pharmacodyn: 2011; 38 5 613 636
19. Kohli U., Pandharipande P., Muszkat M., et al. CYP2A6 genetic variation and dexmedetomidine disposition. Eur J Clin Pharmacol: 2012; 68 6 937 942
20. Kohli U., Muszkat M., Sofowora G. G., et al. Effects of variation in the human alpha2A- and alpha2C-adrenoceptor genes on cognitive tasks and pain perception. Eur J Pain: 2010; 14 2 154 159
21. Kurnik D., Muszkat M., Sofowora G. G., et al. Ethnic and genetic determinants of cardiovascular response to the selective alpha 2-adrenoceptor agonist dexmedetomidine. Hypertension: 2008; 51 2 406 411
22. Kurnik D., Muszkat M., Li C., et al. Genetic variations in the α(2A)-adrenoreceptor are associated with blood pressure response to the agonist dexmedetomidine. Circ Cardiovasc Genet: 2011; 4 2 179 187
23. Yaʇar S., Yava͆ S., Karahalil B. The role of the ADRA2A C1291G genetic polymorphism in response to dexmedetomidine on patients undergoing coronary artery surgery. Mol Biol Rep: 2011; 38 5 3383 3389
24. Muszkat M., Sofowora G. G., Xie H. G., Wood A. J., Stein C. M. Alpha2B adrenergic receptor 301-303 deletion polymorphism and vascular alpha2 adrenergic receptor response. Pharmacogenet Genomics: 2005; 15 1 23 28
25. Dellinger R. P., Levy M. M., Rhodes A., et al. Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med: 2013; 41 2 580 637
26. Anantasit N., Boyd J. H., Walley K. R., Russell J. A. Serious adverse events associated with vasopressin and norepinephrine infusion in septic shock. Crit Care Med: 2014; 42 8 1812 1820
27. Christaki E. Personalized medicine in sepsis: the coming of age. Expert Rev Anti Infect Ther: 2013; 11 7 645 647
28. Reinhart K., Bauer M., Riedemann N. C., Hartog C. S. New approaches to sepsis: molecular diagnostics and biomarkers. Clin Microbiol Rev: 2012; 25 4 609 634
29. Ferrer R., Artigas A. Physiologic parameters as biomarkers: what can we learn from physiologic variables and variation? Crit Care Clin: 2011; 27 2 229 240
30. Talmor D., Sarge T., Malhotra A., et al. Mechanical ventilation guided by esophageal pressure in acute lung injury. N Engl J Med: 2008; 359 20 2095 2104
31. Grasso S., Terragni P., Birocco A., et al. ECMO criteria for influenza A (H1N1)-associated ARDS: role of transpulmonary pressure. Intensive Care Med: 2012; 38 3 395 403
32. Schranz C., Becher T., Schädler D., Weiler N., Möller K. Model-based setting of inspiratory pressure and respiratory rate in pressure-controlled ventilation. Physiol Meas: 2014; 35 3 383 397
33. Soroksky A., Esquinas A. Goal-directed mechanical ventilation: are we aiming at the right goals? A proposal for an alternative approach aiming at optimal lung compliance, guided by esophageal pressure in acute respiratory failure. Crit Care Res Pract: 2012; 2012 12 597932
34. Group B. DW.; Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther: 2001; 69 3 89 95
35. Sandquist M., Wong H. R. Biomarkers of sepsis and their potential value in diagnosis, prognosis and treatment. Expert Rev Clin Immunol: 2014; 10 10 1349 1356
36. Charles P. E., Gibot S. Predicting outcome in patients with sepsis: new biomarkers for old expectations. Crit Care: 2014; 18 1 108
37. Casserly B., Read R., Levy M. M. Multimarker panels in sepsis. Crit Care Clin: 2011; 27 2 391 405
38. Konstantinides S. V. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J: 2014; 35 45 3145 3146
39. Jaff M. R., McMurtry M. S., Archer S. L., et al. American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation: 2011; 123 16 1788 1830
40. Koyner J. L., Parikh C. R. Clinical utility of biomarkers of AKI in cardiac surgery and critical illness. Clin J Am Soc Nephrol: 2013; 8 6 1034 1042
41. Ostermann M. Diagnosis of acute kidney injury: Kidney Disease Improving Global Outcomes criteria and beyond. Curr Opin Crit Care: 2014; 20 6 581 587
42. Alge J. L., Arthur J. M. Biomarkers of AKI: a review of mechanistic relevance and potential therapeutic implications. Clin J Am Soc Nephrol: 2015; 10 1 147 155
43. Gentile L. F., Cuenca A. G., Vanzant E. L., et al. Is there value in plasma cytokine measurements in patients with severe trauma and sepsis? Methods: 2013; 61 1 3 9
44. Vincent J. L., Teixeira L. Sepsis biomarkers. Value and limitations. Am J Respir Crit Care Med: 2014; 190 10 1081 1082
45. Pierrakos C., Vincent J. L. Sepsis biomarkers: a review. Crit Care: 2010; 14 1 R15
46. Christaki E., Giamarellos-Bourboulis E. J. The beginning of personalized medicine in sepsis: small steps to a bright future. Clin Genet: 2014; 86 1 56 61
47. Hack C. E., De Groot E. R., Felt-Bersma R. J., et al. Increased plasma levels of interleukin-6 in sepsis. Blood: 1989; 74 5 1704 1710
48. Damas P., Ledoux D., Nys M., et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg: 1992; 215 4 356 362
49. Patel R. T., Deen K. I., Youngs D., Warwick J., Keighley M. R. Interleukin 6 is a prognostic indicator of outcome in severe intra-abdominal sepsis. Br J Surg: 1994; 81 9 1306 1308
50. Uzzan B., Cohen R., Nicolas P., Cucherat M., Perret G. Y. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med: 2006; 34 7 1996 2003
51. Upadhyay S., Niederman M. S. Biomarkers: what is their benefit in the identification of infection, severity assessment, and management of community-acquired pneumonia? Infect Dis Clin North Am: 2013; 27 1 19 31
52. Müller F., Christ-Crain M., Bregenzer T., et al. ProHOSP Study Group. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest: 2010; 138 1 121 129
53. Masiá M., Gutiérrez F., Shum C., et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest: 2005; 128 4 2223 2229
54. Christ-Crain M., Stolz D., Bingisser R., et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med: 2006; 174 1 84 93
55. Schuetz P., Christ-Crain M., Thomann R., et al. ProHOSP Study Group. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA: 2009; 302 10 1059 1066
56. Schuetz P., Müller B., Christ-Crain M., et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev: 2012; 9 CD007498
57. Tang B. M., Eslick G. D., Craig J. C., McLean A. S. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis: 2007; 7 3 210 217
58. Shehabi Y., Sterba M., Garrett P. M., et al. ProGUARD Study Investigators; ANZICS Clinical Trials Group. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Respir Crit Care Med: 2014; 190 10 1102 1110
59. Jensen J. U., Hein L., Lundgren B., et al. Procalcitonin And Survival Study (PASS) Group. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med: 2011; 39 9 2048 2058
60. Pizzolato E., Ulla M., Galluzzo C., et al. Role of presepsin for the evaluation of sepsis in the emergency department. Clin Chem Lab Med: 2014; 52 10 1395 1400
61. Ackland G. L., Prowle J. R. Presepsin: solving a soluble (CD14) problem in sepsis? Intensive Care Med: 2015; 41 2 351 353
62. Masson S., Caironi P., Spanuth E., et al. ALBIOS Study Investigators. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial. Crit Care: 2014; 18 1 R6
63. Takahashi G., Shibata S., Ishikura H., et al. Presepsin in the prognosis of infectious diseases and diagnosis of infectious disseminated intravascular coagulation: a prospective, multicentre, observational study. Eur J Anaesthesiol: 2015; 32 3 199 206
64. Behnes M., Bertsch T., Lepiorz D., et al. Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment. Crit Care: 2014; 18 5 507
65. Masson S., Caironi P., Fanizza C., et al. Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial. Intensive Care Med: 2015; 41 1 12 20
66. Kofoed K., Andersen O., Kronborg G., et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care: 2007; 11 2 R38
67. Shapiro N. I., Trzeciak S., Hollander J. E., et al. A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Crit Care Med: 2009; 37 1 96 104
68. Gibot S., Béné M. C., Noel R., et al. Combination biomarkers to diagnose sepsis in the critically ill patient. Am J Respir Crit Care Med: 2012; 186 1 65 71
69. Wong H. R., Lindsell C. J., Pettilä V., et al. A multibiomarker-based outcome risk stratification model for adult septic shock. Crit Care Med: 2014; 42 4 781 789
70. Al-Attas O. S., Al-Daghri N. M., Alokail M. S., et al. Adiposity and insulin resistance correlate with telomere length in middle-aged Arabs: the influence of circulating adiponectin. Eur J Endocrinol: 2010; 163 4 601 607
71. The Acute Respiratory Distress Syndrome Network Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med: 2000; 342 18 1301 1308
72. Cross L. J., Matthay M. A. Biomarkers in acute lung injury: insights into the pathogenesis of acute lung injury. Crit Care Clin: 2011; 27 2 355 377
73. Barnett N., Ware L. B. Biomarkers in acute lung injury--marking forward progress. Crit Care Clin: 2011; 27 3 661 683
74. Pittet J. F., Mackersie R. C., Martin T. R., Matthay M. A. Biological markers of acute lung injury: prognostic and pathogenetic significance. Am J Respir Crit Care Med: 1997; 155 4 1187 1205
75. Binnie A., Tsang J. L., dos Santos C. C. Biomarkers in acute respiratory distress syndrome. Curr Opin Crit Care: 2014; 20 1 47 55
76. Janz D. R., Ware L. B. Biomarkers of ALI/ARDS: pathogenesis, discovery, and relevance to clinical trials. Semin Respir Crit Care Med: 2013; 34 4 537 548
77. Bernard G. R., Artigas A., Brigham K. L., et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med: 1994; 149 (3, Pt 1): 818 824
78. Ranieri V. M., Rubenfeld G. D., Thompson B. T., et al. ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin Definition. JAMA: 2012; 307 23 2526 2533
79. Bajwa E. K., Khan U. A., Januzzi J. L., Gong M. N., Thompson B. T., Christiani D. C. Plasma C-reactive protein levels are associated with improved outcome in ARDS. Chest: 2009; 136 2 471 480
80. Kolb M., Margetts P. J., Anthony D. C., Pitossi F., Gauldie J. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest: 2001; 107 12 1529 1536
81. Ward P. A. Role of complement, chemokines, and regulatory cytokines in acute lung injury. Ann N Y Acad Sci: 1996; 796 104 112
82. Goodman R. B., Pugin J., Lee J. S., Matthay M. A. Cytokine-mediated inflammation in acute lung injury. Cytokine Growth Factor Rev: 2003; 14 6 523 535
83. Geiser T., Atabai K., Jarreau P. H., Ware L. B., Pugin J., Matthay M. A. Pulmonary edema fluid from patients with acute lung injury augments in vitro alveolar epithelial repair by an IL-1beta-dependent mechanism. Am J Respir Crit Care Med: 2001; 163 6 1384 1388
84. Geiser T., Jarreau P. H., Atabai K., Matthay M. A. Interleukin-1beta augments in vitro alveolar epithelial repair. Am J Physiol Lung Cell Mol Physiol: 2000; 279 6 L1184 L1190
85. Ranieri V. M., Suter P. M., Tortorella C., et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA: 1999; 282 1 54 61
86. Pugin J., Ricou B., Steinberg K. P., Suter P. M., Martin T. R. Proinflammatory activity in bronchoalveolar lavage fluids from patients with ARDS, a prominent role for interleukin-1. Am J Respir Crit Care Med: 1996; 153 (6, Pt 1): 1850 1856
87. Suter P. M., Suter S., Girardin E., Roux-Lombard P., Grau G. E., Dayer J. M. High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis: 1992; 145 5 1016 1022
88. Meduri G. U., Kohler G., Headley S., Tolley E., Stentz F., Postlethwaite A. Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest: 1995; 108 5 1303 1314
89. Meduri G. U., Headley S., Kohler G., et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest: 1995; 107 4 1062 1073
90. Bastarache J. A., Ware L. B., Bernard G. R. The role of the coagulation cascade in the continuum of sepsis and acute lung injury and acute respiratory distress syndrome. Semin Respir Crit Care Med: 2006; 27 4 365 376
91. Ware L. B., Koyama T., Billheimer D. D., et al. NHLBI ARDS Clinical Trials Network. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest: 2010; 137 2 288 296
92. Ware L. B., Matthay M. A., Parsons P. E., Thompson B. T., Januzzi J. L., Eisner M. D.; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med: 2007; 35 8 1821 1828
93. Moalli R., Doyle J. M., Tahhan H. R., Hasan F. M., Braman S. S., Saldeen T. Fibrinolysis in critically ill patients. Am Rev Respir Dis: 1989; 140 2 287 293
94. Prabhakaran P., Ware L. B., White K. E., Cross M. T., Matthay M. A., Olman M. A. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol: 2003; 285 1 L20 L28
95. Jalkanen V., Yang R., Linko R., et al. FINNALI Study Group. SuPAR and PAI-1 in critically ill, mechanically ventilated patients. Intensive Care Med: 2013; 39 3 489 496
96. Ware L. B., Fang X., Matthay M. A. Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol: 2003; 285 3 L514 L521
97. Wei Y., Wang Z., Su L., et al. Platelet count mediates the contribution of a genetic variant in LRRC16A to ARDS risk. Chest: 2015; 147 3 607 617
98. Verghese G. M., McCormick-Shannon K., Mason R. J., Matthay M. A. Hepatocyte growth factor and keratinocyte growth factor in the pulmonary edema fluid of patients with acute lung injury. Biologic and clinical significance. Am J Respir Crit Care Med: 1998; 158 2 386 394
99. Maitre B., Boussat S., Jean D., et al. Vascular endothelial growth factor synthesis in the acute phase of experimental and clinical lung injury. Eur Respir J: 2001; 18 1 100 106
100. Thickett D. R., Armstrong L., Christie S. J., Millar A. B. Vascular endothelial growth factor may contribute to increased vascular permeability in acute respiratory distress syndrome. Am J Respir Crit Care Med: 2001; 164 9 1601 1605
101. Ware L. B., Kaner R. J., Crystal R. G., et al. VEGF levels in the alveolar compartment do not distinguish between ARDS and hydrostatic pulmonary oedema. Eur Respir J: 2005; 26 1 101 105
102. Thickett D. R., Armstrong L., Millar A. B. A role for vascular endothelial growth factor in acute and resolving lung injury. Am J Respir Crit Care Med: 2002; 166 10 1332 1337
103. Ong T., McClintock D. E., Kallet R. H., Ware L. B., Matthay M. A., Liu K. D. Ratio of angiopoietin-2 to angiopoietin-1 as a predictor of mortality in acute lung injury patients. Crit Care Med: 2010; 38 9 1845 1851
104. Bhandari V., Choo-Wing R., Lee C. G., et al. Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med: 2006; 12 11 1286 1293
105. van der Heijden M., van Nieuw Amerongen G. P., Koolwijk P., van Hinsbergh V. W., Groeneveld A. B. Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients. Thorax: 2008; 63 10 903 909
106. Agrawal A., Matthay M. A., Kangelaris K. N., et al. Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. Am J Respir Crit Care Med: 2013; 187 7 736 742
107. Rubin D. B., Wiener-Kronish J. P., Murray J. F., et al. Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome. J Clin Invest: 1990; 86 2 474 480
108. Modig J., Bagge L. Specific coagulation and fibrinolysis tests as biochemical markers in traumatic-induced adult respiratory distress syndrome. Resuscitation: 1986; 13 2 87 95
109. Moss M., Ackerson L., Gillespie M. K., Moore F. A., Moore E. E., Parsons P. E. von Willebrand factor antigen levels are not predictive for the adult respiratory distress syndrome. Am J Respir Crit Care Med: 1995; 151 1 15 20
110. Ware L. B., Eisner M. D., Thompson B. T., Parsons P. E., Matthay M. A. Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury. Am J Respir Crit Care Med: 2004; 170 7 766 772
111. Griffiths M. J., McAuley D. F. RAGE: a biomarker for acute lung injury. Thorax: 2008; 63 12 1034 1036
112. Su X., Looney M. R., Gupta N., Matthay M. A. Receptor for advanced glycation end-products (RAGE) is an indicator of direct lung injury in models of experimental lung injury. Am J Physiol Lung Cell Mol Physiol: 2009; 297 1 L1 L5
113. Uchida T., Shirasawa M., Ware L. B., et al. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med: 2006; 173 9 1008 1015
114. Fremont R. D., Koyama T., Calfee C. S., et al. Acute lung injury in patients with traumatic injuries: utility of a panel of biomarkers for diagnosis and pathogenesis. J Trauma: 2010; 68 5 1121 1127
115. Bajwa E. K., Januzzi J. L., Gong M. N., Thompson B. T., Christiani D. C. Prognostic value of plasma N-terminal probrain natriuretic peptide levels in the acute respiratory distress syndrome. Crit Care Med: 2008; 36 8 2322 2327
116. Bajwa E. K., Boyce P. D., Januzzi J. L., Gong M. N., Thompson B. T., Christiani D. C. Biomarker evidence of myocardial cell injury is associated with mortality in acute respiratory distress syndrome. Crit Care Med: 2007; 35 11 2484 2490
117. Rivara M. B., Bajwa E. K., Januzzi J. L., Gong M. N., Thompson B. T., Christiani D. C. Prognostic significance of elevated cardiac troponin-T levels in acute respiratory distress syndrome patients. PLoS ONE: 2012; 7 7 e40515
118. Bajwa E. K., Volk J. A., Christiani D. C., et al. National Heart, Lung and Blood Institute Acute Respiratory Distress Syndrome Network. Prognostic and diagnostic value of plasma soluble suppression of tumorigenicity-2 concentrations in acute respiratory distress syndrome. Crit Care Med: 2013; 41 11 2521 2531
119. Ahasic A. M., Zhai R., Su L., et al. IGF1 and IGFBP3 in acute respiratory distress syndrome. Eur J Endocrinol: 2012; 166 1 121 129
120. Ware L. B., Koyama T., Zhao Z., et al. Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome. Crit Care: 2013; 17 5 R253
121. Calfee C. S., Ware L. B., Glidden D. V., et al. National Heart, Blood, and Lung Institute Acute Respiratory Distress Syndrome Network. Use of risk reclassification with multiple biomarkers improves mortality prediction in acute lung injury. Crit Care Med: 2011; 39 4 711 717
122. Calfee C. S., Delucchi K., Parsons P. E., Thompson B. T., Ware L. B., Matthay M. A.; NHLBI ARDS Network. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med: 2014; 2 8 611 620
123. Yende S., Kammerer C. M., Angus D. C. Genetics and proteomics: deciphering gene association studies in critical illness. Crit Care: 2006; 10 4 227
124. Meyer N. J., Garcia J. G. Wading into the genomic pool to unravel acute lung injury genetics. Proc Am Thorac Soc: 2007; 4 1 69 76
125. Flores C. Host genetics shapes adult sepsis survival. Lancet Respir Med: 2015; 3 1 7 8
126. Sorensen T. I., Nielsen G. G., Andersen P. K., Teasdale T. W. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med: 1988; 318 12 727 732
127. Sutherland A. M., Walley K. R. Bench-to-bedside review: association of genetic variation with sepsis. Crit Care: 2009; 13 2 210
128. Lin M. T., Albertson T. E. Genomic polymorphisms in sepsis. Crit Care Med: 2004; 32 2 569 579
129. Man M., Close S. L., Shaw A. D., et al. Beyond single-marker analyses: mining whole genome scans for insights into treatment responses in severe sepsis. Pharmacogenomics J: 2013; 13 3 218 226
130. Rautanen A., Mills T. C., Gordon A. C., et al. ESICM/ECCRN GenOSept Investigators. Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. Lancet Respir Med: 2015; 3 1 53 60
131. Bernard G. R., Vincent J. L., Laterre P. F., et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med: 2001; 344 10 699 709
132. Wong H. R., Cvijanovich N., Lin R., et al. Identification of pediatric septic shock subclasses based on genome-wide expression profiling. BMC Med: 2009; 7 34
133. Wong H. R., Cvijanovich N. Z., Anas N., et al. Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am J Respir Crit Care Med: 2015; 191 3 309 315
134. Flores C., Ma S. F., Maresso K., Ahmed O., Garcia J. G. Genomics of acute lung injury. Semin Respir Crit Care Med: 2006; 27 4 389 395
135. Meyer N. J. Beyond single-nucleotide polymorphisms: genetics, genomics, and other 'omic approaches to acute respiratory distress syndrome. Clin Chest Med: 2014; 35 4 673 684
136. Meyer N. J., Christie J. D. Genetic heterogeneity and risk of acute respiratory distress syndrome. Semin Respir Crit Care Med: 2013; 34 4 459 474
137. Gao L., Barnes K. C. Recent advances in genetic predisposition to clinical acute lung injury. Am J Physiol Lung Cell Mol Physiol: 2009; 296 5 L713 L725
138. Tejera P., Meyer N. J., Chen F., et al. Distinct and replicable genetic risk factors for acute respiratory distress syndrome of pulmonary or extrapulmonary origin. J Med Genet: 2012; 49 11 671 680
139. Christie J. D., Wurfel M. M., Feng R., et al. Trauma ALI SNP Consortium (TASC) investigators. Genome wide association identifies PPFIA1 as a candidate gene for acute lung injury risk following major trauma. PLoS ONE: 2012; 7 1 e28268
140. Howrylak J. A., Dolinay T., Lucht L., et al. Discovery of the gene signature for acute lung injury in patients with sepsis. Physiol Genomics: 2009; 37 2 133 139